A5091400921- Cancer survivorship and care
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Prostate Cancer Treatment and Research
- Cancer Treatment and Pharmacology
- Palliative Care and End-of-Life Issues
- Childhood Cancer Survivors' Quality of Life
- Statistical Methods in Clinical Trials
- Clinical practice guidelines implementation
- Prostate Cancer Diagnosis and Treatment
- Patient-Provider Communication in Healthcare
- Ethics in Clinical Research
- Nausea and vomiting management
- Global Cancer Incidence and Screening
- Pain Management and Opioid Use
- Radiopharmaceutical Chemistry and Applications
- Meta-analysis and systematic reviews
- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Cancer-related cognitive impairment studies
- Multiple Myeloma Research and Treatments
- Bladder and Urothelial Cancer Treatments
- Endometrial and Cervical Cancer Treatments
- Management of metastatic bone disease
- Complementary and Alternative Medicine Studies
University of North Carolina at Chapel Hill
2016-2025
UNC Lineberger Comprehensive Cancer Center
2016-2025
University of North Carolina Health Care
2015-2024
Memorial Sloan Kettering Cancer Center
2013-2023
Perspectives Charter School
2015-2023
Mayo Clinic in Arizona
2015-2023
Indiana University School of Medicine
2016-2023
Faculty of Media
2019-2022
Linde (United States)
2014-2019
Public Health Department
2016-2019
Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent who had not received previous
Purpose To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer castrate levels of testosterone. Methods A committee investigators experienced conducting defined new consensus criteria by reviewing previous criteria, Response Evaluation Criteria Solid Tumors (RECIST), emerging trial data. Results The Prostate Cancer Clinical Trials Working Group (PCWG2) recommends a two-objective paradigm: (1) controlling, relieving,...
Purpose There is growing interest to enhance symptom monitoring during routine cancer care using patient-reported outcomes, but evidence of impact on clinical outcomes limited. Methods We randomly assigned patients receiving outpatient chemotherapy for advanced solid tumors at Memorial Sloan Kettering Cancer Center report 12 common symptoms via tablet computers or receive usual consisting the discretion clinicians. Those with home received weekly e-mail prompts between visits. Treating...
Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations succeed those from prior Prostate Cancer Clinical Trials Working Groups.An international expert committee of investigators (the Group 3 [PCWG3]) was reconvened expanded met in 2012-2015 formulate updated criteria on basis emerging data validation studies 2 recommendations.PCWG3...
An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO) offers timely direction to ASCO's membership following publication or presentation potentially practice-changing data from major studies. This PCO addresses the integration palliative care services into standard oncology practice at time a person is diagnosed with metastatic advanced cancer.Palliative frequently misconstrued as synonymous end-of-life care. Palliative focused on relief suffering, in all its...
To integrate the patient perspective into adverse event reporting, National Cancer Institute developed a patient-reported outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE).
<h3>Importance</h3> Patient-reported outcome (PRO) data from clinical trials can provide valuable evidence to inform shared decision making, labeling claims, guidelines, and health policy; however, the PRO content of trial protocols is often suboptimal. The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement was published in 2013 aims improve completeness by providing evidence-based recommendations minimum set items be addressed, but it does not PRO-specific...
A patient wants to know about symptoms she may have from a prescription drug is taking.Consulting the label's "Adverse Reactions" section, finds wealth of data.Little does realize that
In cancer treatment trials, the standard source of adverse symptom data is clinician reporting by use items from National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE). Patient self-reporting has been proposed as an additional source, but implications such a shift are not understood. Patients with lung receiving chemotherapy and their clinicians independently reported six CTCAE symptoms Karnofsky Performance Status longitudinally at sequential office visits. To...
Recording patient-reported outcomes electronically in real time and allowing clinicians to review longitudinal PRO reports can improve patients' quality of life, enhance patient–clinician communication, reduce emergency department utilization, lengthen survival.
The Patient-Centered Outcomes Research Institute (PCORI) was established as part of the US Patient Protection and Affordable Care Act 2010 to fund patient-centered comparative clinical effectiveness research, extending concept patient-centeredness from health care delivery research. In United States, outcomes research is new not defined in legislation, rationale unclear many. this Viewpoint, we address 2 related questions: What does patientcenteredness mean? Why conduct patientcentered...
This study reports 2-year survival outcomes among patients with advanced nonprogressive stage IIA to IV lung cancer randomized symptom monitoring during chemotherapy via web-based patient-reported vs standard scheduled imaging after treatment detect symptomatic recurrence.
Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, visceral organs. There is no standard of care.In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid receive either sorafenib (400-mg tablet once daily) matching placebo. Crossover group was permitted for placebo who had disease...
To update the guideline to include new anticancer agents, antiemetics, and antiemetic regimens provide recommendations on use of dexamethasone as a prophylactic in patients receiving checkpoint inhibitors (CPIs).ASCO convened an Expert Panel updated systematic review randomized controlled trials (RCTs) meta-analyses RCTs published between June 1, 2016, January 24, 2020. address CPI question, we conducted that evaluated addition chemotherapy.The reviews included 3 publications from search 10...